Large Majority of Americans Say Consideration of Clinical Trial Participation Should be a Part of Regular Health Care

New National Public Opinion Survey Reveals Willingness to Participate in Clinical Trials; Importance of Trials Reflecting the Population; Concerns About Sharing Personal Health Information Have Grown  
Research America logo

Arlington, VA – December 5, 2023 According to survey findings released today, an overwhelming majority of Americans (87%) agree that health care professionals should discuss clinical trials with patients diagnosed with a disease as part of their standard of care. Further, sixty-one (61%) percent agree that consideration of clinical trial participation should be a part of regular health care whether patients are healthy or ill, up from 44% in 2017. Commissioned by Research!America in partnership with the Association of Clinical Research Organizations (ACRO), the October 2023 national survey captures Americans views on clinical trials and clinical research. ( View slide deck of survey results. )

“We are pleased to partner again with Research!America to survey public attitudes toward clinical trials, which are essential to the development of new drugs and new treatments for the people who need them,” said Doug Peddicord, Executive Director of ACRO. “Especially important is that the public believes that clinical trials should be part of everyday health care and that physicians and other healthcare providers should discuss clinical trial options with their patients.”

Despite widespread support for the incorporation of clinical research into health care, only 36% of respondents say their doctor or other health care professional has talked with them about medical, health, or clinical research. That said, this is an encouraging jump from 19% in 2017 who said so. Overwhelmingly, respondents prefer getting information about clinical trials from their doctor or health care provider (77%) rather than other sources and say that doctors and health care providers (50%) have the greatest responsibility in educating the public about clinical trials.

While approximately 8 in 10 respondents say they have heard of a clinical trial, only 26% say they or someone in their family has ever participated in one, up from 18% in 2017. However, of those that had not participated in a clinical trial, 49% are willing to do so. Respondents noted lack of trust (57%) as the top reason individuals do not participate in clinical trials, which grew from 38% in 2017. Adverse side effects (52%), up from 34% in 2017, and lack of awareness/information (55%) follow closely.

Most Americans feel positively about clinical trials with many agreeing that they benefit from clinical research and its findings (73%). Factors important to clinical trial participation are understanding potential risks and benefits (72%), competence and reputation of people or the institution conducting the research (71%) and having an expert guide through the clinical trials process (60%). Eight in 10 respondents said they were likely to participate in a clinical trial at a traditional site (like a hospital or a doctor’s office), but many also indicated that they would be likely to participate at a non-traditional site with 75% likely to participate at a home site and 67% at a community site (like a community health center, clinic, CVS, Walgreens, etc.).

“Clinical trials are essential to progress in medical research. These new survey findings highlight that Americans are not only interested in learning more about clinical trials, they are willing to get involved,” said Mary Woolley, President and CEO of Research!America. “Though a growing lack of trust is cause for concern, it is heartening to see Americans’ strong support for clinical research. It’s clear that it’s time to expand discussion between patients and health care professionals, ensure access to clinical trials, and improve participant diversity.”

Though most respondents expressed willingness to share personal health information, the survey reveals a downward shift in public attitudes on this topic that calls for attention from the research community. Respondents say they are willing to share their health information:

  • To advance medical and health research (71%), down from 82% in 2017.
  • So researchers can better understand diseases and develop new cures (70%), down from 84% in 2017;
  • So health care provide­­rs can improve patient care (68%), down from 79% in 2017;
  • So public health officials can better track diseases, disabilities, and their causes (63%), down from 74% in 2017.

Data suggests that confidence in the U.S. system for reviewing the effectiveness and safety of new medicines and medical technologies has increased with 7 in 10 saying they are confident in the current system, up from 63% in 2017. Respondents are split, however, on the speed with which the U.S. Food and Drug Administration (FDA) should act.

Additional highlights from the Research!America/ACRO survey include:

  • Seven in 10 respondents want to find out more about taking part in clinical trials.
  • Eighty-five percent say it is important that clinical trials populations are representative of the U.S. population.
  • Most all agree that clinical trials are important to advancing science (90%) and improving health (87%).
  • Only a quarter of respondents are familiar with clinicaltrials.gov and clinical research organizations (CROs). Twenty-five percent of respondents have heard of clinicaltrials.gov, slightly up from 22% in 2017, and 24% have heard of clinical research organizations (CROs), no significant change from 2017.

The online survey was conducted by Zogby Analytics on behalf of Research!America in October 2023, among 1,005 adults plus 1,207 additional adults for minority oversampling. The survey has a theoretical sampling error of +/- 3.1 percentage points.

For questions about the survey, or to set up an interview with Mary Woolley, contact Taylarr Lopez, Director of Communications for Research!America, at 571-482-2719 or tlopez@researchamerica.org with press inquiries.

###

About the Association of Clinical Research Organizations (ACRO)

Founded in 2002, ACRO represents the world’s leading clinical research and technology organizations, which provide specialized services that are integral to the development of drugs, biologics and medical devices. ACRO and its members advocate on a global basis for safe, ethical, high-quality medical research so patients can benefit from the development of new treatments and therapies. Our members are dedicated to helping their clients bring efficiency, innovation and value to the clinical research process.

About Research!America Research!America is a non-profit medical and health research advocacy alliance which advocates for science, discovery, and innovation to achieve better health for all. Visit www.researchamerica.org.

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS